|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Bone Marrow and Stem Cell Transplant Center,
Division of Hematology and Oncology, Winship Cancer Institute, and the
Department of Biostatistics, Emory University, Atlanta, GA; and the
Department of Pediatric Hematology-Oncology, University of Cincinnati
Children's Hospital Medical Center, Cincinnati, OH.
Relapse is the major cause of death after allogeneic bone marrow
transplantation (BMT). This study tested the hypothesis that the
numbers of donor mononuclear cells, lymphocytes, and CD34+
cells influence relapse and event-free survival (EFS) after BMT. The
study population consisted of 113 consecutive patients with hematologic
malignancies who underwent non-T-cell-depleted BMT from HLA-matched
siblings. Sixty-four patients had low-risk diagnoses (ALL/AML CR1, MDS
RA/RARS, and CML CP1); 49 patients had high-risk diagnoses (all
others). CD34+ cells, T cells, B cells, natural killer
cells, monocytes, and a rare population of CD3 Despite significant improvements in supportive care
in the past 30 years, aggregate 5-year survival for all patients
undergoing allogeneic transplantation from human leukocyte antigen
(HLA)-matched siblings remains approximately 50%.1-7
Numerous factors, including the patient's disease stratum, age,
conditioning regimen, and type of graft-versus-host disease (GVHD)
prophylaxis, influence the probability of survival after
allogeneic transplantation.1,8,9
Optimal numbers for each cell type in the bone marrow (BM) or
peripheral blood progenitor cell allograft are unknown. Recipients of
T-cell-depleted allografts have decreased risk for
GVHD10,11 but experience delayed immune reconstitution and
have increased risk for infection, graft failure, and
relapse.12-14 Larger numbers of colony-forming unit
(CFU)-granulocyte macrophage colonies in bone marrow allografts have
been associated with improved survival after transplantation and faster
hematopoietic engraftment.15 Larger numbers of
transplanted CD34+ cells have been correlated with faster
hematopoietic reconstitution after allogeneic
transplantation16-20 and increased risk for acute GVHD
after transplantation.21 Transplantation with fewer than 1 × 106 CD34+ cells/kg from T-cell-depleted
allogeneic bone marrow and peripheral stem cell grafts have been
associated with increased relapse and treatment-related
death.16,22 In one study, transplantation of more than
3 × 106 CD34+ cells/kg resulted in a 14%
relapse rate versus a 48% rate for recipients of lower
CD34+ cell doses.22
The role of type 1 and type 2 dendritic cells (DCs) in regulating
immune reconstitution, GVHD, and GvT effects after allogeneic transplantation has become an area of increasing interest. Type 1 DC
(DC1) promotes Th1 immune responses in responding CD4+ T
cells characterized by enhanced interferon- We undertook a prospective analysis of the cellular constituents of the
bone marrow allograft to help identify those factors that might predict
relapse, GVHD, and event-free survival (EFS) among patients undergoing
transplantation for hematologic malignancy. The CD3 Patient characteristics
Bone marrow harvest and processing
T-cell proliferation assays Subpopulations of bone marrow mononuclear cells were isolated by fluorescence-activated cell sorter (FACS) to more than 95% purity and tested as stimulators in a one-way mixed lymphocyte reduction (MLR) assay. Purified bone marrow cells irradiated to 1500 cGy and serial dilutions were prepared starting at 50 000 cells/well to 400 cells/well in 96-well culture plates containing RPMI media with 50 ng/mL IL-3, 100 ng/mL GM-CSF, and 10% AB human plasma.
Then 50 000 allogeneic peripheral blood mononuclear cells from a
normal donor were added to each well. Cultures were maintained in a
humidified atmosphere at 37°C in 5% CO2 for 5 days.
Cultures were pulsed with 1 µCi/well of 3H-thymidine for
18 hours before they were harvested and counted on a beta-counter on
the fifth day of culture.
Analysis of cellular constituents of the graft Three- and 4-color flow cytometry was used to enumerate the frequency of T cells, B cells, monocytes, natural killer (NK) cells, dendritic cells, CD34+ cells, and the subset of CD34+, CD38 cells in the graft using
Paint-A-Gate (Becton Dickinson, San Jose, CA).32
The number of transplanted cells in each subset was determined by
multiplying the percentage of nucleated (CD45+) cells with
each phenotype by the number of nucleated cells in the graft. All cell
transplantation data are expressed as the number of cells transplanted
per kilogram body weight of the recipient. Aliquots of the transplant
product were cultured in methyl cellulose according to standard methods
for a subset of 77 patients, and the number of CFU of various types
were scored at 10 to 12 days according to standard
definitions.33
Conditioning regimens Patients with acute lymphoblastic leukemia (ALL) and patients with advanced AML and NHL underwent a conditioning regimen consisting of total body irradiation (TBI) at a dose of 200 cGy twice daily for 3 days in combination with cyclophosphamide (Cy/TBI) at a dose of 60 mg/kg daily for 2 days. Patients with CML, low-risk MDS, and AML in first remission typically received busulfan at a dose of 1 mg/kg every 6 hours for a total of 16 doses, in combination with cyclophosphamide at a dose of 60 mg/kg daily for 2 days (Bu/Cy), or Bu/Cy plus a single infusion of cytosine arabinoside at a dose of 2 gm/m2 (Bu/Cy/Ara-C). Patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), NHL, and Hodgkin disease (HD) received the combination of Bu/Cy and etoposide at 10 mg/kg daily for 3 days (Bu/Cy/VP16).34GVHD prophylaxis and management GVHD prophylaxis and management consisted of a short course of methotrexate at doses of 15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6, and 11. Leucovorin rescue was administered for 4 doses every 6 hours beginning 24 hours after the second, third and fourth doses. Patients received tacrolimus starting on the day before transplantation and continuing through day 180.35 Acute GVHD was initially managed with prednisone or methylprednisolone at a dose of 2 mg/kg; patients whose GVHD failed to respond to a combination of prednisone with Prograf were treated with equine ATG at a dose of 30 mg/kg daily for 4 days. Chronic GVHD was typically managed with combinations of Prograf, prednisone, and mycophenolate.Prophylactic and empiric antibiotic therapy All patients received prophylactic antibiotics by mouth. These consisted of fluconazole (400 mg, 4 times a day), acyclovir (400 mg, 3 times a day) penicillin VK (500 mg, twice a day), and ciprofloxacin (500 mg, twice a day) starting on the day before transplantation and continuing until an absolute neutrophil count greater than 500 was reached. Empiric treatment of febrile neutropenia included ceftazidime, vancomycin, and amphotericin B as clinically indicated. Fluconazole was continued until day 75 after transplantation. Trimethoprim-sulfamethoxazole was prescribed at a dose of 1 double-strength tablet 3 times a week starting on day 30 and continuing until day 180, or until all immunosuppressive medication was discontinued for the patient. Blood samples were assessed weekly by qualitative polymerase chain reaction (PCR) amplification of cytomegalovirus (CMV) DNA for the presence of CMV after transplantation; patients with positive PCR findings underwent pre-emptive treatment with ganciclovir for at least 3 weeks.Outcome measurements Analyses were performed on the reference date of September 1, 2000. Median follow-up for patients alive on the reference date was 3 years (range, 1-5 years). Overall survival was defined as the time elapsed from bone marrow transplantation (BMT) to death (from whatever cause), or to last-documented contact with the patient. EFS was defined as survival with no evidence of relapse. Engraftment of granulocytes was defined as the first of 3 consecutive days after BMT on which the absolute neutrophil count was greater than 500/µL. Engraftment of platelets was defined as the first day after BMT on which the platelet count was greater than 20 000/µL and the patient had not received a platelet transfusion for the 7 preceding days. Acute GVHD (aGVHD) was defined as occurring before day 100 and was graded using standard IBMTR criteria (one patient had the first documented occurrence of aGVHD on day 104).35 Chronic GVHD (cGVHD) was assessed at 100 days, 6 months after transplantation, and annually thereafter. The time to develop GVHD was defined as the time from BMT to the first occurrence of either aGVHD or cGVHD. Patients who had relapses were censored for the subsequent occurrence of GVHD because management of relapse usually included maneuvers that could induce GVHD. Causes of death were classified according to IBMTR criteria.36 Relapse was listed as the primary cause of death for any patient who died after the diagnosis of relapse or disease progression. GVHD was considered the primary cause of death if patients died of infection during active treatment for aGVHD or cGVHD.Statistical methods Baseline characteristics between groups of patients were compared using the Student t test. Clinical outcomes (death, relapse, infection, GVHD) were correlated with patient characteristics (diagnosis, age, conditioning regimens) and donor characteristics (age, sex, graft constituents) in univariate analyses using Cox regression and SPSS software version 5.1. Multivariate regression analysis performed according to the Cox proportional hazards regression model37 used EFS as the dependent variable and the factors thought to be associated with post-transplant EFS patient age, risk
classification, and numbers of nucleated cells, T cells, and
CD34+ cells transplantedas covariates. In addition, other
factors that were correlated with EFS at the significance level of
P < .05 in the univariate analyses were also included.
Multivariate Cox regression models for the entire group of patients and
subsets of patients at low risk and high risk were performed using all individual factors as covariates, without pre-set inclusion or exclusion criteria for each factor. The entire study population of 113 patients was subdivided based on the number of nucleated cells,
CD34+ cells, CD4bright cells, or
CD3+ T cells in the graft. Relative quantity (low,
intermediate, or high) was used as a factor for survival analyses.
Level of significance assumed to be significant in comparisons of
survival curves by the log-rank test was P < .05.
Clinical characteristics that affected relapse-free survival after transplantation Diagnoses, median ages, and genders of the 64 patients in the low-risk group and of the 49 patients in the high-risk group are shown in Table 1. The most frequent indications for transplantation were CML (40 patients) followed by AML (28 patients), MDS (16 patients), NHL (12 patients), and ALL (8 patients). Median ages of patients in the low-risk group (45 years) and the high-risk group (42 years) were similar. Male patients were more prevalent in the high-risk group. Actuarial EFS rates in the low-risk group were 84%, 68%, and 58% at 100 days, 1 year, and 3 years after transplantation, respectively, versus 57%, 27%, and 14%, respectively, for patients in the high-risk group. Analysis of overall survival showed a similar pattern (data not shown). Univariate analysis of clinical factors associated with relapse or death after transplantation showed that high-risk status was the most significant factor associated with worse EFS (P < .0001; Table 2). Other patient-related factors significantly associated with increased death or relapse after transplantation included male gender (relative risk [RR], 1.9; 95% confidence interval [CI], 1.1-3.8; P = .017) and the use of TBI in the conditioning regime (RR, 2.3; 95% CI, 1.1-4.8; P = .03). Of note, TBI was used only in a subset of 10 patients with AML, ALL, and NHL.
Graft characteristics that affected EFS after transplantation Patients who received more CD34+ cells with the allograft had improved EFS after transplantation (RR, 0.79, associated with an increase of 1 × 106 donor CD34+ cells/kg in the graft; 95% CI, 0.64-0.97; P = .028; Table 3). In contrast, the numbers of transplanted CD34+, CD38 cells were not
significantly associated with EFS after BMT. Larger numbers of donor
cells with the phenotype CD3, CD4bright,
CD8, low side-scatter were associated with increased
deaths after transplantation (RR, 2.2, associated with an increase of
1 × 106 cells/kg; 95% CI, 1.2-3.8;
P = .0072). Total numbers of CFU and nucleated cells
transplanted and numbers of donor T cells, B cells, NK cells, and
monocytes were not significantly associated with the risk for relapse
or with death after transplantation (Table 3).
CD4bright,
CD3 low side-scatter cells
had the same phenotype as the "plasmacytoid T cell" (Figure
1A-B)31 and the
lineage-negative (Lin), HLADR+,
CD123+ CD11c dendritic cell progenitor
(DC2p).27 Ninety percent of the CD123+,
Lin, HLADR+ low side-scatter cells (Figure
1D-E) expressed relatively bright levels of CD4 (Figure
1F).27 Only 10% of the CD3,
CD4bright, CD8, low side-scatter cells
expressed CD11c (Figure 1C), indicating that they are distinct from the
Lin, HLADR+, CD123dim
CD11c+ (DC1). In particular, the Lin,
HLADR+, CD123dim CD11c+ (DC1)
(Figure 1G, 1I) populations had higher side-scatter and lower CD4
expression than CD4bright or CD123bright
populations (compare Figures 1B, 1E with 1H). Twenty-nine paired samples of bone marrow were separately analyzed for the content of (1)
CD3, CD4bright, CD8, low
side-scatter cells, (2) Lin HLADR+,
CD123bright CD11c cells (DC2p), and (3)
Lin HLADR+, CD123dim
CD11c+ cells (DC1). The number of CD4bright
dendritic cell progenitors in the grafts was nearly identical to the
number of Lin, HLADR+, CD123+,
CD11c cells (ratio of CD123bright to
CD4bright cells, 1.2; r = 0.92, Figure
2A). In contrast, the number of DC1 was
more than twice the number of CD3, CD4bright,
CD8, low side-scatter cells (Figure 2A). FACS-isolated
CD4bright, CD123bright, Lin BM
cells cultured in the presence of IL-3 and GM-CSF had the typical
appearance of "veiled" DC (cells with a ruffled extension of their
cytoplasm, observed under light microscopy) and efficiently elicited an
MLR from HLA-mismatched allogeneic lymphocytes (Figure 2B).
Patients who underwent transplantation with fewer CD4bright DCs had improved EFS after allogeneic BMT A striking effect on enhanced EFS was seen among patients at low risk who received fewer CD4bright DCs in their grafts (Figure 3A). Patients at low risk in group 1(DC) (less than 0.6 × 106 CD4bright DCs/kg) had a 3-year actuarial EFS of 80%, whereas those in group 3(DC) (more than 0.9 × 106 CD4bright DCs/kg) had a 3-year actuarial EFS of only 48% (Figure 3A; P = .009 comparing group 1(DC) versus group 3(DC)). Analysis of the 49 patients at high risk divided according to the content of CD4bright DC showed a trend toward better survival among recipients of fewer CD4bright DC (P = .09; Figure 3B). In contrast, patients at low risk who received larger numbers of CD34+ cells had significantly improved EFS (Figure 3C). Transplantation with larger numbers of total nucleated cells was also associated with improved EFS among patients at low risk only (not shown), whereas the content of CD3+ cells in the graft did not affect EFS in either low-risk or high-risk subsets (not shown).
Multivariate model of EFS A multivariate Cox regression model was built using factors significantly associated (P < .05) with EFS in the univariate analyses (Tables 2, 3). In addition, patient and graft characteristics hypothesized as potentially significant with respect to EFS were also included (age, number of nucleated cells transplanted, numbers of donor T cells transplanted). Seven individual factors were entered into the multivariate models without P value thresholds for inclusion or exclusion. The multivariate model was tested on the entire patient population (n = 113) and on the subsets of patients at low risk (n = 64) and high risk (n = 49). TBI was not included in the multivariate model because only 10 patients underwent TBI-based conditioning (1 ALL, 6 AML, 2 NHL, 2 MM), and TBI was not a significant factor in univariate or multivariate analyses of EFS when the patient population was stratified by disease diagnosis (data not shown). Covariates independently associated with increased risk for death or relapse in all 113 patients included risk strata (RR, 2.8; P = .0002), male gender (RR, 1.8; P = .04), and number of donor CD4bright DC (RR, 2.0; P = .03) in the bone marrow allograft (Table 4). In contrast, larger numbers of donor CD34+ cells (RR, 0.76; P = .027) were associated with improved EFS in the group of 113 patients (Table 4). Separate analysis of the subset of 64 patients at low risk showed that CD4bright DC content remained a highly significant factor for worse EFS (RR, 21; P = .0008). Transplantation with larger numbers of donor-nucleated cells (RR, 0.41; P = .05) and larger numbers of donor CD34+ cells (RR, 0.71; P = .1) were also associated with improved EFS among patients at low risk (Table 4). In the subset of 49 patients at high risk, no covariate was significantly associated with EFS in the multivariate analysis (Table 4). The use of conditional entry criteria for inclusion of covariates in the multivariate model (P < .05 or .1) did not alter the role of gender, risk, CD34+ cell content, and CD4bright DC cell content as independently significant factors (data not shown). Multivariate analyses based on overall survival as the clinical end-point gave similar results in multivariate analyses (data not shown).
Increased numbers of CD4bright DCs in the graft were associated with increased relapse after transplantation Overall, 60 of 113 patients died by the reference date; 21 of 64 (33%) were from the low-risk group, and 39 of 49 (80%) were from the high-risk group. Relapse was the most frequent primary cause of death, and fatal relapse occurred in 7 of 64 (11%) patients at low risk and 20 of 49 (41%) patients at high risk at a median of 331 days after transplantation. Thirteen deaths (3 relapse, 10 nonrelapse) occurred among patients who underwent transplantation with less than 0.6 × 106 CD4bright DC cells/kg (group 1(DC)). Twenty-one deaths (11 relapse, 10 nonrelapse) occurred in the group 2(DC) patients, and 26 deaths (13 relapse, 13 nonrelapse) occurred in the group 3(DC) patients (Table 5). Cumulative incidences of relapse in groups 1(DC), 2(DC), and 3(DC) were compared after stratification on risk. The incidence of relapse was 33% among low-risk patients who received the largest number of CD4bright DC versus 8% among low-risk patients who received the fewest DC (Figure 4A; P = .01; group 1(DC) vs group 3(DC)). The incidence of relapse was 48% among high-risk patients who received the highest and the intermediate numbers of CD4bright DC versus only 22% among high-risk patients who received the fewest CD4bright DC (Figure 4B; P = .01; group 1(DC) vs group 2(DC) or group 3(DC)). A multivariate model using the same covariates as in Table 4 evaluated relapse as a single clinical end-point (Table 6). Risk strata (RR, 3.8; P = .0023) and age (RR, 0.94; P = .003) were independently associated with relapse in the entire group of 113 patients. Among patients at low risk, relapses were fewer among recipients of a larger number of nucleated cells (RR, 0.2; P = .03) and were more frequent among recipients of more CD4bright DCs (RR, 114; P = .0074). Among patients at high risk, the only covariate significantly associated with relapse was age (RR 0.92; P = .0028).
Incidence of acute GVHD was not associated with any graft constituent Among the entire study population, aGVHD developed in 24 of 113 (21%) patients a median of 38 days after transplantation. Twenty of 113 (18%) patients experienced grade 2 to 4 aGVHD, and 8 of 113 (7%) patients experienced grade 3 or 4 aGVHD. Twenty-one patients with aGVHD were treated with systemic steroids. No single donor factor (Tables 2, 3) or combination of factors (Table 4) was significantly associated (P < .05) with the risk for aGVHD in univariate or multivariate analyses (data not shown). In particular, the median number of CD4bright DCs among patients in whom aGVHD developed (0.83 ± 0.33 × 106/kg) was not significantly different than the corresponding value of those patients in whom aGVHD did not develop (0.7 ± 0.4 × 106/kg; P = .2).Incidence of cGVHD varied according to the content of CD4bright DCs in the graft cGVHD developed in 34 of 113 (30%) patients at a median of 182 days after transplantation. Nine patients had limited-grade and 25 patients had extensive-grade cGVHD. Thirty-one patients received systemic corticosteroids for the treatment of cGVHD. Among 82 patients who survived to day 100 and were evaluable for cGVHD, a higher content of CD4bright DC was associated with a lower risk for cGVHD (RR, 0.42; 95% CI, 0.17-1.05; P = .06). Larger numbers of CD34+ cells in the graft were also associated with lower risk for cGVHD (RR, 0.74; 95% CI, 0.56-1.0; P = .05). cGVHD was observed more frequently in men (RR, 2.3; 95% CI, 1.1-4.8; P = .03) and in recipients of larger numbers of CD56+ "NK-like" T cells (RR, 1.1; 95% CI, 1.0-1.3; P = .03). Patient age and content of total numbers of nucleated cells, CD3+ T cells, or other T-cell subsets were not significantly associated with the development of cGVHD in univariate analyses (data not shown). The mean number of CD4bright DC among patients in whom cGVHD developed was significantly lower than the corresponding value for those patients in whom aGVHD did not develop (0.68 ± 0.37 × 106/kg versus 0.85 ± 0.4 × 106/kg, respectively; P = .03). Figure 5 shows that the cumulative incidence of cGVHD was lower among recipients of more than 0.9 × 106/kg CD4bright DC/kg compared with recipients of less than 0.6 × 106 and 0.6 to 0.9 × 106 CD4bright DC/kg (22% vs 52% and 50%, respectively; P = .04). Multivariate analysis using the same covariates shown in Table 4 revealed that gender was the only factor independently associated with increased risk for cGVHD (RR for males, 2.7; 95% CI, 1.1-6.7; P = .03).
Patients transplanted with more CD34+ cells had faster engraftment and decreased incidence of death from infection after transplantation Univariate and multivariate analyses demonstrated the CD34+ cell dose was the single significant covariate associated with the time to achieve granulocyte engraftment (RR, 1.2; P = .02) and platelet engraftment (RR, 1.3; P = .003). Patients who received grafts containing more than 3.5 × 106 CD34+ cells/kg (group 3(CD34)) had granulocyte and platelet engraftment after 18 and 26 days, respectively. Patients who received less than 2.5 × 106 CD34+ cells/kg (group 1(CD34)) had significantly delayed granulocyte engraftment (22 days; P = .02) and platelet engraftment (37 days; P = .008). Death from infectious causes (other than interstitial pneumonia) occurred in 14 patients at a median of 38 days after transplantation. Comparing causes of death according to the CD34+ cell dose in the bone marrow graft, 29 of 41 (71%) patients in group 1(CD34) died by the reference date, with 10 of 29 deaths attributable to infections (Table 7). Within group 2(CD34), 13 of 33 (39%) patients died, with 3 deaths attributable to infection. Within group 3(CD34), 18 of 39 (46%) patients died, with 1 death attributable to infection. Multivariate analysis of covariates associated with nonrelapse mortality confirmed the significance of the CD34+ cell dose (Table 8). Among the entire group of 113 patients, risk strata (RR, 2.3; P = .02), age (RR, 1.1; P = .002), and CD34+ cell dose (RR, 0.58; P = .0042) were associated with nonrelapse mortality in the multivariate model. No covariates were significantly associated with nonrelapse mortality among patients at low risk. Among patients at high risk, nonrelapse death was more frequent among older patients (RR, 1.1; P = .0018) and less frequent among recipients of larger numbers of CD34+ cells (RR, 0.51; P = .012; Table 8).
Our hypothesis was that significant interdonor variability in the cellular constituents of the graft would lead to quantitative and qualitative differences in hematopoietic engraftment, GVHD, and relapse. The novel finding in this study was that larger numbers of CD4bright DCs had adverse effects on survival and were associated with increased post-transplantation relapse and decreased cGVHD. In contrast to previous reports of increased relapse associated with T-cell-depleted allografts, the number of transplanted T cells or various T-cell subsets was not significantly correlated with either survival or relapse.38 As predicted, the CD34+ cell dose positively affected engraftment kinetics and survival after transplantation (Table 3).16,22,39 Barrett et al22 recently described increased relapse among recipients of T-cell-depleted allografts transplanted with fewer numbers of CD34+ donor cells. In contrast, patients in the present study who received fewer CD34+ donor cells in the context of a T-cell-replete allograft did not experience a significantly increased incidence of relapse (Tables 6, 7). A lower dose of donor CD34+ cells was associated with a higher incidence of death from infection (Table 7) and increased nonrelapse-related death (Table 8). Donor CD34+ myeloid and lymphoid progenitors may differentiate rapidly into donor-derived granulocytes and T cells and B cell, thus accelerating hematopoietic and immune reconstitution after transplantation.40 In contrast to a previous report, the number of CFU in the allograft was not significantly correlated (P < .05) with the kinetics of hematopoietic reconstitution, EFS, or overall survival after transplantation.15 As has been previously reported,18 larger numbers of total nucleated cells transplanted were associated with improved EFS, though the association was limited to the subset of low-risk patients in the present study (Tables 4, 6). The CD4bright DC2p measured in this study (Figure
1) have an overlapping phenotype with the previously described
dendritic cell progenitor (Lin Overall, recipients of more CD34+ cells and fewer
CD4bright DCs had superior EFS than patients who received
fewer CD34+ cells or more DC. The independent association
of CD4bright DCs with EFS is supported by the lack of
correlation between the numbers of transplanted CD34+ cells
and CD4bright DCs (r = 0.22) and the
independent significance of nucleated cells, CD34+ cells,
and CD4bright DCs as covariates in multivariate analysis. A
number of hypotheses may explain the role of donor
CD4bright DCs in influencing relapse and cGVHD after
transplantation. Larger numbers of the CD4bright DCs in
allogeneic bone marrow grafts may shift the developing donor immune
system toward a type 2 response characterized by decreased Th1 cellular
immune responses, and a decreased graft-versus-leukemia effect.30,41,42 Donor DCs may capture allo-antigen through apoptotic bodies of residual host hematopoietic cells and induce tolerance to minor histocompatability antigens in donor T cells (indirect antigen presentation or "cross-priming"), thereby
inhibiting the graft-versus-leukemia effect.43-45 Such an
antigen-specific effect could occur as one of the initial events in the
early period after transplantation or during subsequent de novo T-cell
development of donor stem cells in the host thymic
microenvironment.46 In addition, donor DC2p may function
as immunoregulatory cells that synthesize IFN- The effect of larger or smaller numbers of transplanted donor dendritic
cell subsets with the DC1 phenotype (Lin
We greatly acknowledge Dr William J. Eley for his helpful discussions. We thank Sylvia Ennis for assistance in preparing the manuscript.
Submitted July 6, 2000; accepted January 17, 2001.
Supported (E.K.W.) by the Doris Duke Charitable Foundation, the Cancer Research Institute, and the Leukemia and Lymphoma Society.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Edmund K. Waller, Bone Marrow and Stem Cell Transplant Center, Emory University, Suite 1003, 1639 Pierce Dr, Atlanta, GA 30322; e-mail: ewaller{at}emory.edu.
1.
Wagner JE, Zahurak M, Piantadosi S, et al.
Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits.
J Clin Oncol.
1992;10:779-789 2. Demuynck H, Verhoef GE, Zachee P, et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant. 1996;17:745-751[Medline] [Order article via Infotrieve]. 3. Lamparelli T, Van Lint MT, Gualandi F, et al. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Bone Marrow Transplant. 1997;20:1057-1062[CrossRef][Medline] [Order article via Infotrieve]. 4. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant. 1996;18:741-746[Medline] [Order article via Infotrieve]. 5. Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time: a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 1996;17:13-18[Medline] [Order article via Infotrieve]. 6. Ustun C, Arslan O, Beksac M, et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant. 1999;5:28-35[CrossRef][Medline] [Order article via Infotrieve]. 7. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 1999;5:341-346[CrossRef][Medline] [Order article via Infotrieve].
8.
Szydlo R, Goldman JM, Klein JP, et al.
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
J Clin Oncol.
1997;15:1767-1777 9. Grigg AP, Szer J, Beresford J, et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol. 1999;107:409-418[CrossRef][Medline] [Order article via Infotrieve].
10.
Atkinson K, Horowitz MM, Gale RP, et al.
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.
Blood.
1990;75:2459-2464
11.
Verdonck LF, de Gast GC, van Heugten HG, Dekker AW.
A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation.
Blood.
1990;75:776-780
12.
Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E.
Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts.
Blood.
1996;87:3984-3992 13. Delain M, Cahn JY, Racadot E, et al. Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. Leuk Lymphoma. 1993;11:359-368[Medline] [Order article via Infotrieve].
14.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562 15. Bacigalupo A, Piaggio G, Podesta M, et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:221-226[Medline] [Order article via Infotrieve].
16.
Mavroudis D, Read E, Cottler-Fox M, et al.
CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.
Blood.
1996;88:3223-3229 17. Miflin G, Russell NH, Hutchinson RM, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies: an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. 1997;19:9-13[CrossRef][Medline] [Order article via Infotrieve].
18.
Sierra J, Storer B, Hansen JA, et al.
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.
Blood.
1997;89:4226-4235 19. Brown RA, Adkins D, Goodnough LT, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol. 1997;15:3067-3074[Abstract]. 20. Ilhan O, Arslan O, Arat M, et al. The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci. 1999;20:69-71[CrossRef][Medline] [Order article via Infotrieve].
21.
Przepiorka D, Smith T, Folloder J, et al.
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.
Blood.
1999;94:1465-1470 22. Bahceci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol. 2000;108:408-414[CrossRef][Medline] [Order article via Infotrieve].
23.
Rissoan MC, Soumelis V, Kadowak IN, et al.
Reciprocal control of T helper cell and dendritic cell differentiation.
Science.
1999;283:1183-1186 24. Ye Z, Gee AP, Bowers WE, Lamb LS, Turner MW, Henslee-Downey PJ. In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cells. Bone Marrow Transplant. 1996;18:997-1008[Medline] [Order article via Infotrieve].
25.
Ryncarz RE, Anasetti C.
Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells.
Blood.
1998;91:3892-3900
26.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor
27.
Olweus J, BitMansour A, Warnke R, et al.
Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin.
Proc Natl Acad Sci U S A.
1997;94:12551-12556 28. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302[CrossRef][Medline] [Order article via Infotrieve].
29.
Shlomchik WD, Couzens MS, Tang CB, et al.
Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
Science.
1999;285:412-415
30.
Arpinati M, Green CL, Heimfield S, Heuser JE, Anasetti C.
Granulocyte-colony stimulating factor mobilizes T helper-2-inducing dendritic cells.
Blood.
2000;95:2484-2490
31.
Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ.
The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand.
J Exp Med.
1997;185:1101-1111
32.
Waller EK, Olweus J, Lund-Johansen F, et al.
The "common stem cell" hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors.
Blood.
1995;85:2422-2435
33.
Guerriero A, Worford L, Holland HK, Guo GR, Sheehan K, Waller EK.
Thrombopoietin is synthesized by bone marrow stromal cells.
Blood.
1997;90:3444-3455 34. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230[Medline] [Order article via Infotrieve].
35.
Ratanatharathorn V, Nash RA, Przepiorka D, et al.
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Blood.
1998;92:2303-2314 36. Bortin MM, Ringden O, Horowitz MM, Rozman C, Weiner RS, Rimm AA. Temporal relationships between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplantation. 1989;4:339-344[Medline] [Order article via Infotrieve]. 37. Cox DR, Oakes D. Proportional Hazards Model: Analysis of Survival Data. New York, NY: Chapman and Hall; 1984:104-106.
38.
Marmont AM, Horowitz MM, Gale RP, et al.
T-cell depletion of HLA-identical transplants in leukemia.
Blood.
1991;78:2120-2130
39.
Korbling M, Huh YO, Durett A, et al.
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
Blood.
1995;86:2842-2848 40. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91:661-672[CrossRef][Medline] [Order article via Infotrieve].
41.
Khanna A, Morelli AE, Zhong C, Takayama T, Lu L, Thomson AW.
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo.
J Immunol.
2000;164:1346-1354 42. Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant. 1996;2:118-125[Medline] [Order article via Infotrieve].
43.
Heath WR, Kurts C, Miller JF, Carbone FR.
Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.
J Exp Med.
1998;187:1549-1553
44.
Liu YJ, Blom B.
Introduction: Th2-inducing DC2 for immunotherapy.
Blood.
2000;95:2482-2483
45.
Steinman RM, Turley S, Mellman I, Inaba K.
The induction of tolerance by dendritic cells that have captured apoptotic cells.
J Exp Med.
2000;191:411-416
46.
Mackall CL, Fleisher TA, Brown MR, et al.
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy [see comments].
N Engl J Med.
1995;332:143-149
47.
Siegal FP, Kadowaki N, Shodell M, et al.
The nature of the principal type 1 interferon-producing cells in human blood.
Science.
1999;284:1835-1837 48. Reddy V. Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper polarization prior to host alloantigen presentation [letter]. Blood. 2000;96:2636.
49.
Herbst B, Kohler G, Mackensen A, et al.
In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the Birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type.
Blood.
1996;88:2541-2548
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Koyama, D. Hashimoto, K. Aoyama, K.-i. Matsuoka, K. Karube, H. Niiro, M. Harada, M. Tanimoto, K. Akashi, and T. Teshima Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells Blood, February 26, 2009; 113(9): 2088 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Talarn, A. Urbano-Ispizua, R. Martino, J. A. Perez-Simon, M. Batlle, C. Herrera, M. Granell, A. Gaya, M. Torrebadell, F. Fernandez-Aviles, et al. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome Haematologica, December 1, 2007; 92(12): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Shaughnessy, C. Bachier, C. F. LeMaistre, C. Akay, B. H. Pollock, and Y. Gazitt Granulocyte Colony-Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte-Macrophage Colony-Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors Stem Cells, July 1, 2006; 24(7): 1789 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. McKenna, A.-S. Beignon, and N. Bhardwaj Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity J. Virol., January 1, 2005; 79(1): 17 - 27. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Moseman, X. Liang, A. J. Dawson, A. Panoskaltsis-Mortari, A. M. Krieg, Y.-J. Liu, B. R. Blazar, and W. Chen Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells J. Immunol., October 1, 2004; 173(7): 4433 - 4442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Fagnoni, B. Oliviero, G. Giorgiani, P. De Stefano, A. Deho, C. Zibera, N. Gibelli, R. Maccario, G. Da Prada, M. Zecca, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation Blood, July 1, 2004; 104(1): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Reddy, J. A. Iturraspe, A. C. Tzolas, H.-U. Meier-Kriesche, J. Schold, and J. R. Wingard Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease Blood, June 1, 2004; 103(11): 4330 - 4335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, S. Antonenko, J. M. Sederstrom, X. Liang, A. S. H. Chan, H. Kanzler, B. Blom, B. R. Blazar, and Y.-J. Liu Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors Blood, April 1, 2004; 103(7): 2547 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Palucka, J. Gatlin, J. P. Blanck, M. W. Melkus, S. Clayton, H. Ueno, E. T. Kraus, P. Cravens, L. Bennett, A. Padgett-Thomas, et al. Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors Blood, November 1, 2003; 102(9): 3302 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Szabolcs, K.-D. Park, M. Reese, L. Marti, G. Broadwater, and J. Kurtzberg Absolute Values of Dendritic Cell Subsets in Bone Marrow, Cord Blood, and Peripheral Blood Enumerated by a Novel Method Stem Cells, May 1, 2003; 21(3): 296 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. A. MacDonald, V. Rowe, C. Filippich, R. Thomas, A. D. Clouston, J. K. Welply, D. N. J. Hart, J. L. M. Ferrara, and G. R. Hill Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation Blood, March 1, 2003; 101(5): 2033 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine Stem Cell Mobilization Hematology, January 1, 2003; 2003(1): 419 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rocha, M. Labopin, E. Gluckman, R. Powles, W. Arcese, A. Bacigalupo, J. Reiffers, A. Iriondo, O. Ringden, T. Ruutu, et al. Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey J. Clin. Oncol., November 1, 2002; 20(21): 4324 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Teshima, P. Reddy, K. P. Lowler, M. A. KuKuruga, C. Liu, K. R. Cooke, and J. L. M. Ferrara Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8alpha + dendritic cells and reduces experimental acute graft-versus-host disease Blood, March 1, 2002; 99(5): 1825 - 1832. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(IFN-
) or 3 (
).
Equations for the best-fit lines comparing the relation between
populations 1 and 2 (slope, 1.2; r = 0.92) and between
populations 1 and 3 (slope, 2.7; r = 0.85) are shown. (B)
Ability of unfractionated bone marrow cells (
). FACS-isolated CD123
) and FACS-isolated Lin
) to stimulate proliferation of
allogeneic lymphocytes in an MLR was assessed after 5 day co-culture in
media containing 10% AB
), group 2 (
), and group 3 (
and promote the
survival of mature DC2,